With rising skin disorders, the dermatology sector has emerged as one of the top-growing therapeutic areas within the Indian pharmaceutical market. Interestingly, dermatology’s substantial growth not only highlights its critical role in addressing diverse skin conditions but also points to the evolving consumer awareness and prioritization of dermatological care.
Over the years, Glenmark Pharmaceuticals Ltd (GPL) has carved out a significant niche within the dermatology segment. GPL is primarily focused on building a global formulation business with Branded, Generics, and OTC segments in the therapy areas of Dermatology, Respiratory and Oncology. Glenmark continues to outperform the market in the key therapy areas of Cardiac, Dermatology and Respiratory.
With a market share of 7.88% in the dermatology sector as per as per MAT September 2024, Glenmark’s strategic focus and expertise in dermatology reflect its commitment to advancing dermatological care and addressing a broad spectrum of skin health needs.
In an email interaction with Financial Express.com, Alok Malik, President & Business Head – India Formulations, Glenmark Pharmaceuticals Ltd. talked about Glenmark’s dermatology business growth and priorities, prevalence of skin disorders prevalent in India, upcoming plans and more. Excerpt:
What is India’s position in the global map of the dermatology segment? How is Glenmark navigating this space?
The dermatology market in the country has seen significant growth in the last few years. With growing awareness about skincare conditions fueled by growth in the middle class and rising disposable incomes, people are becoming more receptive towards skin-related treatments. The market size for dermatology is estimated at Rs 13,340 crore (as per Pharmatrack July 2024 data) and is growing at a steady rate of 8% compound annual growth rate (CAGR). The dermatology segment in the Indian Pharmaceutical Market (IPM) is expected to grow at 11-12%.
Glenmark has consistently grown in the Indian market in terms of our presence and product offerings with a market share of 7.88% (as per MAT Sept 2024 data) in the dermatology segment. This can be attributed to our comprehensive and innovative product range for managing various dermatological disorders. We are ranked number 2 among dermatologists for prescribing derma therapy. Our Emollient portfolio became Number 1 in dermatologists’ prescriptions in the protective emollients category according to the IQVIA medical audit for MAT Dec 2023 (as per Projected Prescriptions from Jan 2023 to Dec 2023) in India. The company has also recorded strong growth with successful product launches in the segment, which has further strengthened our strategic positioning.
Glenmark’s made its initial foray into the dermatology therapy area 45 years ago in 1979 with the launch of “Candid Cream.” This brand has been a bestseller to this day. In the past five to six years, our company’s derma segment has experienced strong dynamics with important product launches. We launched MINYM – a 4% Minocycline topical Gel for the treatment of moderate to severe acne. We received the AWACS award for Best Launch for both Cysteo (Cysteamine 5%), used in the treatment of melasma, and Super-bioavailable Itraconazole 130 mg, an antifungal treatment. Additionally, Aprezo was recognized for its effectiveness in managing psoriasis. Episoft AC has also been recognised as the first Dermatologist – prescribed brand in Acne/Acne Vulgaris indication under the Emollient & protective preparations category, as per CMARC MAT October 2023.
In terms of contributions in Q1 FY 2025, Candid Powder has grown by 22.1% and La Shield by 12.1%. During the quarter, the Scalpe portfolio witnessed strong uptake, particularly for Scalpe PRO. Our company expects the derma segment to grow by 10-12% by 2027. Moreover, our company will undertake strategic acquisitions and partnerships. For example, the co-marketing agreement with Pfizer firm over abrocitinib under the same brand names like JABRYUS in India for atopic dermatitis. Thus, Glenmark has a broad perspective of developing dermatological solutions and producing innovative methods of treatment for better patient-oriented outcomes.
With respect to disease burden, what are some of the major skin disorders prevalent in India? How Glenmark is catering to these disease areas?
As stated by DocGenie, and a report from the Indian Journal of Dermatology, Venereology, and Leprology (IJDVL), India has 20 common skin conditions. Out of these, acne is very common among adolescents and young adults. Dermatitis is also a common condition, where there are various types of eczema. Atopic dermatitis is highly prevalent in children. The fungal infection is a condition that is common in both urban and rural setups due to the humid climate of India. On the other hand, psoriasis has emerged as a chronic autoimmune condition that is marked by red, scaly patches of the skin and has seriously impacted the quality of life of those affected. Furthermore, vitiligo is a major dermatologic problem in India because it involves the loss of skin colour and white patches, which are very visible and cause psychological trauma to individuals.
Glenmark made its foray into the dermatology therapy area over four decades ago and has maintained a robust presence in this segment. Currently, we have a comprehensive range of 120+ brands in our portfolio, managing 15+ key skin-related ailments. Glenmark’s commitment to providing innovative treatment options `to patients enables the company to challenge the established treatment paradigms and deliver promising solutions. The company’s focus on building a global formulation business with branded, generics, and over-the-counter (OTC) segments in therapy areas of dermatology, respiratory and oncology significantly contributes to its growth.
In the market analysis ending Sept 2024, the dermatology sector in the Indian Pharmaceutical Market (IPM) grew 7.8% on a moving annual total (MAT) basis whereas Glenmark outperformed the overall market with a growth of 13.7%. Also, our key brands in various subcategories such as Systemic and Topical Antifungal, Topical Corticosteroids, Hair care, Cosmetology, and Acne delivered consistent market-beating growth and gained market shares in their respective categories. These factors have collectively contributed to our growth numbers in this segment. We have a pan India presence, with a team consisting of 1500+ field force, which is the largest in the industry. Our expertise is backed by our legacy of 45 years and innovation that holds significance for both HCPs and patients alike.
What are key diseases that are driving the market growth of Glenmark’s dermatology pipeline in India as well as the global market?
Earlier in 2024, we collaborated with Pfizer to market abrocitinib in India. Developed by Pfizer, abrocitinib has received marketing authorization for adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It has also been approved by the USFDA, European Medicines Agency (EMA), and other regulatory bodies. Also, to establish the use of customized sunscreen in various disease conditions, we launched The Indian Sunscreen Forum (ISF) which is a newly formed expert group comprising 18 leading dermatologists. This forum aims to build the first-ever consensus on the use of customized sunscreen specifically tailored for the Indian population across different disease conditions. The findings from this consensus will be disseminated to a broader audience, particularly dermatologists, to enhance understanding and adoption.
With respect to our markets globally, in 2023, we secured approval from the US health regulator for the generic Tacrolimus ointment, intended for the treatment of moderate to severe atopic dermatitis. Furthermore, in September 2023, we also acquired exclusive rights from Cosmo to commercialize Winlevi (clascoterone cream 1%) for acne treatment in 15 EU countries, the UK, and South Africa.
What are your upcoming plans for the segment in the country? Are you planning to explore new disease areas in the segment?
Glenmark believes in continuous innovation across therapy areas. There are many upcoming innovations and product developments in Dermatology. Episoft AC has launched its high SPF (SPF 50+) SKU for patients who are on procedural care for acne and pigmentary disorders. Episoft AC SPF 50+ helps us to strengthen our footprint in the non-clinical management of acne mainly with aesthetic procedures. This is a boon for patients whose 1st priority is sun protection along with hydration.
We are continuously exploring opportunities to enhance our dermatology portfolio, with the goal of addressing the diverse needs of patients. As we continue to focus on innovating in acne therapy to deliver superior patient care & treatment outcomes, we are working on a range of innovative products that will set new standards in the treatment of acne. These upcoming products are designed with cutting-edge technology and patient-centered insights, ensuring they address the unmet needs of those suffering from acne. By offering more effective, personalized, and accessible solutions, we are not only enhancing patient outcomes but also reinforcing our position as a leader in the acne therapy space.
Our strategic investments in research and development, combined with our deep understanding of dermatological needs, will enable us to bring these transformative products to market. This will further strengthen our reputation as pioneers in this therapy area and solidify our long-term leadership in the country.
Any plans for pipeline expansion or product launches in this segment in FY25? What are some of the dermatology therapy growth drivers in the past few years in IPM? What are some of the focal areas for Glenmark to stay ahead of the market competition?
Glenmark is one of the top players in the Immunotherapy space with Tacrolimus & Mometasone brands being the No. 1 brands in the segment. We will continue to focus on our key categories such as Systemic and Topical Antifungal, Psoriasis, Atopic dermatitis, Immunomodulator, Cosmetic dermatology mainly Emollients, Protectives and Anti-Acne. We will be leveraging growth of modern trade channels by making our over-the-counter products available on online platforms for better reach and visibility. We are committed to expanding our presence in tier-1 cities and rural towns, aiming to reach a wider population with our innovative product offerings. Our mission is to consistently grow our market share to become the number 1 player- for the segment in India.
We are actively exploring various emerging opportunities within the dermatology space in India. It is one of our key therapeutic areas for growth and innovation and the company aims to maintain a leadership position in this segment. Glenmark is enhancing its stakeholder management approach with improved doctor engagement and direct-to-consumer outreach through microsites and chatbots, indicating a proactive strategy to engage with stakeholders in the dermatology space. Our plans to leverage our existing portfolio and new product launches highlight a broader strategy for expansion in this segment.
The Indian Dermatology Drugs Market Analysis Report 2022 notes that skin diseases such as acne, psoriasis, eczema, and atopic dermatitis have been increasingly prevalent. This rise in the level of skin conditions has, in turn, aided considerably in increasing the demand for dermatological treatments and products. There is, moreover, growing awareness regarding skin health and aesthetics, especially among the youth. This increased awareness has led to more demand for dermatology products in the therapeutic and cosmetic fields. More demand for complete skin care routines and preventive measures further boosts market growth. All these factors put together act as propellants for strong growth in dermatological therapies within the pharmaceutical market in India. We expect this trend to continue over the foreseeable future, reflecting the increasing emphasis placed on skin health and the continuous developments in dermatologic treatments. Further to enhance the therapy space we will be soon coming up with innovative therapies like Ruxolitinib as this molecule has shown good results in Vitiligo & Atopic Dermatitis Management.
What are the challenges with respect to diagnosis and treatment that people with skin disorders tend to face in India? How Glenmark is addressing these challenges?
A lack of awareness about diseases related to the skin and treatment options leads to late presentations, which worsens a patient’s condition. It is often difficult to diagnose skin diseases because of overlapping symptoms. In addition, advanced diagnostic tools are not available in the non-urban areas. Social stigma due to skin diseases can cause psychological problems and may even discourage a person from seeking treatment. Moreover, biologics and other advanced treatments for chronic conditions such as psoriasis and atopic dermatitis are, to an extent, held back because of their high cost and limited availability, especially in rural regions. That makes it necessary to remove the barriers if one has to work for better patient care and outcomes.
Hence, in an effort to combat misinformation and promote acceptance, Glenmark and IADVL (The Indian Association of Dermatologists, Venereologists, and Leprologists) conducted a unique painting competition named “Empathy in Every Stroke” on World Vitiligo Day, June 25, 2024. The competition aimed to spotlight the significance of awareness, understanding, and treatment for vitiligo patients. Dermatologists from across the country submitted over 150 entries, each creatively depicting patient’s journeys with vitiligo and highlighting the importance of embracing diversity. These entries are now featured on postcards and calendars, symbolizing our dedication to empathy, acceptance, and respect for those affected by vitiligo. This initiative reflects our commitment to inclusivity and making a positive impact. By challenging misconceptions, we aim to foster a more inclusive society and make a meaningful difference in the lives of vitiligo patients.
The Skin and Hair Facebook page is an innovative collaboration with doctors to share social media videos that raise awareness about various skin conditions and the correct approaches to managing them. Over 1,000 videos on skin health have already been posted, with more being added daily to continue educating and informing the public. Additionally, we plan to raise awareness among patients regarding the benefits of customized sunscreen, ensuring that this important information reaches those who need it most.
Anything else that you would like to add?
Glenmark’s dermatology portfolio encompasses a range of leading brands, each catering to specific skincare requirements. La Shield sunscreen is a household name that effectively protects patients from harmful sun rays and is customized for skincare. Minym Gel, India’s first topical Minocycline 4% Gel, addresses concerns related to acne treatment with potent antibacterial and anti-inflammatory properties.
Momate offers a potent steroid treatment for Eczema, Atopic Dermatitis and Psoriasis by reducing symptoms like swelling, itching, redness and many others, and Oral & Topical Antifungals such as Canditral, Syntran & Lulican add strength to the overall derma portfolio.
We focus on using advanced technology, following strict guidelines, and keeping patients at the center of allour offerings. Key efforts towards these include top-notch manufacturing, strict compliance with regulations, and prioritizing patient safety. Glenmark also engages with patients through large-scale education and support programs, aiming to improve healthcare access and outcomes.
Recurrent and clinically unresponsive dermatophytosis is being increasingly encountered in our country. Misuse of topical corticosteroids, a high number of familial contacts, poor compliance to treatment over periods of years, and various host factors, seem to have all contributed to the same. At Glenmark, we firmly believe that adherence to treatment is crucial in the fight against fungal infections. To support HCPs in improving patient outcomes we actively partner with them to raise awareness through dedicated patient education camps. These camps aim to empower patients by educating them on the Do’s and Don’ts of managing fungal infections and highlighting the importance of completing prescribed treatments to minimize recurrence and relapse. Our team alongside HCPs engages directly with patients, distributing patient education leaflets and discussing best practices in managing fungal infections. Conducting 500 to 600 camps monthly, we reach and educate over 5000 patients every month reinforcing our commitment to enhancing treatment adherence and supporting HCPs in delivering better patient care.
We are proud to be the first company in India to launch a 30-capsule HDPE bottle pack to improve treatment adherence in fungal infection. This innovative packaging solution has been widely appreciated by HCPs across India, recognizing our commitment to improving patient outcomes and making treatment regimens more manageable. Our efforts are setting a new standard in the fight against fungal infection. Episoft AC is a novel 2 in 1 formula (moisturizer and sunscreen together) primarily promoted in Acne/Acne Vulgaris, recommended by dermatologists to simplify daily skincare routine. Episoft AC has novel ingredients that help acne patients with 2 essential aspects i.e. skin hydration and sun protection (reducing treatment-led side effects such as dryness, erythema and post-inflammatory pigmentation). This expertly formulated product offers deep hydration and broad-spectrum SPF-30 protection, ensuring the skin stays moisturized and shielded from harmful UV rays for up to 8 hours, providing an instant feeling of reduced dryness in just 30 minutes after application, with noticeable improvements within 8 days. Its innovative blend, including Capric Triglyceride, D- Panthenol, Avobenzone, Octinoxate, Oxybenzone, and Glycerin, regenerates the epidermal barrier within 24 hours, leaving no white cast and is suitable for all skin types.
This product brings ultimate convenience and compliance to skin care routine of acne patients by not only supporting their treatment journey with anti-acne medications, but also reducing the unnecessary layering of skin with multiple products at one go (different applications for moisturizer and sunscreen). Episoft AC formulation’s sensorial feel (lightweight, non-comedogenic and essential sun protection credentials) makes it a preferred brand for dermatologists in acne management.
Going forward, Glenmark aims to be among the top 10 players, by revenue, in the Indian Pharmaceutical Market (IPM), while maintaining its focus on Dermatology, Respiratory, Oncology, Cardio-vascular and Diabetes as key therapeutic areas.
